Premium
Tissue protein biomarker candidates to predict progression of esophageal squamous cell carcinoma and precancerous lesions
Author(s) -
Wang Meng,
Smith Jennifer S.,
Wei WenQiang
Publication year - 2018
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/nyas.13863
Subject(s) - medicine , biomarker , oncology , disease , stage (stratigraphy) , esophageal squamous cell carcinoma , basal cell , prospective cohort study , survival rate , incidence (geometry) , cancer , biology , paleontology , biochemistry , physics , optics
Esophageal squamous cell carcinoma (ESCC) is one of the most predominant malignancies worldwide. The 5‐year survival rate is still relatively low due to few symptoms presenting with the early disease, diagnosis at middle to late stage, and high risk of recurrence after therapy. Novel protein biomarkers for early detection and treatment of ESCC have the potential to reduce incidence and mortality rates, and significantly prolong the 5‐year survival rate. To date, several ESCC biomarkers are being investigated for screening, diagnosis, and treatment to decrease the disease burden. This review summarizes recent developments in candidate protein biomarkers for early diagnosis, predictors for precancerous disease progression, and prognosis of ESCC. Protein biomarkers that enable identification of the different pathologic grades of ESCC will need to be identified. ESCC biomarkers have the potential to improve screening and treatment strategies; multicenter prospective studies with large sample sizes will be required to confirm the usefulness of these candidate biomarkers.